Generic Medicine Info
Indications and Dosage
Diabetic neuropathy
Adult: 50 mg tid.
Description: Epalrestat inhibits aldose reductase enzyme which catalyses the conversion of glucose to sorbitol. Accumulation of sorbitol in certain cells occurs only in conditions of hyperglycaemia and resulting in hyperosmotic effect which may be involved in pathogenesis of some diabetic complications. Aldose reducatse inhibitors have no effect on blood-glucose concentrations.
MIMS Class
Antidiabetic Agents
Buckingham R (ed). Epalrestat. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 16/09/2014.

Disclaimer: This information is independently developed by MIMS based on Epalrestat from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in